Menu
US
sars-cov-2-drug-repurposing-candidates-1920x400
Case Study

NIH NCATS case study: using accelerated screening research for SARS-CoV-2 drug repurposing candidates

Drug Repurposing can be an effective way to identify novel treatments for diseases, especially when time is of the essence.

Research scientists at National Center for Advancing Translational Sciences (NCATS), a part of the NIH, embarked on a drug repurposing strategy as the quickest route to generating data that would help the pharma industry drive towards an effective treatment for the COVID-19 virus.

Find out how in a matter of months the NCATS team was able to screen 3,384 molecular entities and narrow them down to a field of 25 quality "hits" capable of disrupting SARS-Cov-2 S1 protein:ACE2 receptor binding in this case study.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

NIH NCATS case study: using accelerated screening research for SARS-CoV-2 drug repurposing candidates

Download Case Study